Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Andreas PinterKilian EyerichAntonio CostanzoAlyssa GarreltsChristopher SchusterCan MertAnastasia LampropoulouKonstantinos FotiouJulia-Tatjana MaulKim A PappPublished in: The Journal of dermatological treatment (2024)
Overall, the results do not clearly indicate that treating patients early is critical in achieving optimal patient outcomes. Furthermore, patients treated with ixekizumab show numerically higher response rates relative to other individual biologics irrespective of disease duration.